Abstract:Objective To investigate the possibility of using melanoma antigen-1 (MAGE-1) peptide as a tumor vaccine to treat hepatocellular carcinoma ( HCC).Methods The expressions of MAGE-1 in 8 HCC cell lines and in liver cancer tissue from a patient were detected using RT-PCR. The type of human leucocyte antigen I (HLA I) of both 8 HCC cell lines and peripheral blood mononuclear cells of the patient was detected using a microcytotoxicity method to screen out target cell lines for the cytotoxicity assay. Peripheral blood mononuclear cells from the HCC patient pulsed with an MAGE-1 pepticle ( NYKCRFPEI) were used as antigen presenting cells. Autogenous peripheral blood mononuclear cells were stimulated with antigen presenting cells every 7 days for 4 times to elicit cytotoxic T lymphocytes. The phenotype of effector cells was analyzed using flow cytometry. The cytotoxicity of effector cells was detected with a lactate dehydrogenase releasing assay.Results The expressions of both MAGE-1 and HLA-A24 were detected in BEL7405 cell line which were used as the positive target cell line in the cytotoxicity assay. The expression of MAGE-1 alone was detected in HLE, BEL7402, BEL7404, QGY7703 and SMMC7721 cell lines, and the expression of neither MAGE-1 nor HLA-A24 was shown in QGY 7701 and HpG2 cell lines. The last 7 cell lines could be used as negative target cell lines in the cytotoxicity assay. Peripheral blood mononuclear cells expanded 32 folds during 28-day culture. The ratio of CD3(+) T cells increased by 16% (from 54% to 70%), and the ratio of CD8(+) T cells increased by 20% (from 36% to 56%) during 28-day culture. When the ratio of effector cells to target cells was 10: 1, effector cells exhibited 62.5% cytotoxicity against autogenous lymphoblasts pulsed with the peptide (NYKCRFPEI) of MAGE-1 antigen, 40.25% cytotoxicity against BEL7405 cells, compared with 17.88% cytolysis observed against autogenous lymphoblasts, 19.55% against HLE cells, and 1.6% against QGY7701 cells. When the ratio of effector cells to target cells was 3. 3:1, the cytotoxicity of effector cells against the peptide pulsed autogenous lymphoblasts was 53.6%, which was much higher against autogenous lymphoblasts, HLE cells and QGY7701 cells at 15.6%, 13% and 1%, respectively.Conclusion The results demonstrate that cytotoxic T lymphocytes with the ability to specifically lyse target cells expressing both MAGE-1 and HLA-A24 could be successfully induced by the MAGE-1 peptide NYKCRFPEI in vitro. This indicates that a good result might be anticipated if this peptide is used as a tumor vaccine to treat HLA-A24 HCC patients.

[Melanoma Antigen-3 Expression in Human Hepatocellular Carcinoma].

Proliferative effect of MAGE-A9 deletion mutant on human breast cancer MCF-7 cells

Expression of Melanoma Antigen Gene in Cell Lines Originated from Hepatocellular Carcinoma Cells

Expression of the MAGE-1 Gene in Human Hepatocellular Carcinomas

[Expression of MAGE-B Genes in Hepatocellular Carcinoma].

Specific CD8+ T Cell Responses to HLA-A2 Restricted MAGE-A3 P271–279 Peptide in Hepatocellular Carcinoma Patients Without Vaccination

Induction of Cytotoxic T Lymphocytes from the Hepatocellular Carcinoma Patients by Using MAGE-3- Gene-Derived and HLA-A2-restricted Peptide

Evaluation of MAGE-1 and MAGE-3 As Tumour-Specific Markers to Detect Blood Dissemination of Hepatocellular Carcinoma Cells.

Mrna of MAGE Genes As Specific Markers in Detection of Tumor Cells in the Peripheral Blood of Patients with Hepatocellular Carcinoma

MAGE-1 and Related MAGE Gene Expression May Be Associated with Hepatocellular Carcinoma

Immune Responses to NY--ESO--1 and MAGE--A3 Peptides in Hepatocellular Carcinoma Patients

[Expression and Clinical Significance of MAGE-4 Gene in Human Hepatocellular Carcinoma].

Peptide Derived from MAGE-3 Epitope Induced Cytotoxic T Lymphocytes of Hepatocellular Carcinoma Patient in Vitro

Expression of melanoma antigen gene-3(MAGE-3)in gastric neoplasm and its clinical significance

[The Genetic Polymorphism of Melanoma-Associated Antigen 1 in Chinese Normal Donors and Hepatoma Patients].

Expression of Cancer-Testis Antigens in Hepatocellular Carcinoma

The Expression of Cancer-Testis Antigen MAGE-A1、MAGE-C2 and SSX-1 Mrna in Hepatocellular Carcinoma

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of A Hepatocellular Carcinoma Patient Using Melanoma Antigen-1 (Mage-1) Peptide

Expression of MAGE-A1 and Its Clinical Signficance in Hepatocellular Carcinoma

Expression of A, G and B melanoma antigen genes in human hepatocellular carcinoma.

Identification of a Naturally Presented MAGE-A3 Epitope on the Surface of HLE Cell Line by Mass Spectrometry